Management of Renal Disease

  • Author: Mohamed G. Atta, MD, MPH (More Info)
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 3/14/17 (What's New)

Summary

  • Boosted PIs and tenofovir DF have been associated with significant declines in renal function in combination and individually[Goicoechea 2008; Gallant 2009; Morlat 2013]
  • Tenofovir DF should be avoided in patients with eGFR < 60 mL/min/1.73 m2[Lucas 2014]
  • Tenofovir AF is less nephrotoxic than tenofovir DF in clinical trials and is recommended as either preferred over or as an appropriate alternative to tenofovir DF in US guidelines

Action required

Keywords: Renal Complications, Treatment Complications

©2020 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.